

ASX/Media Release

RESULTS OF ANNUAL GENERAL MEETING

SYDNEY, AUSTRALIA – 26 November 2021 – [Immutep Limited](#) (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”) advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and Listing Rule 3.13.2.

Please be advised that all resolutions in the Company’s 2021 Notice of Annual General Meeting were passed by the requisite majorities at today’s AGM.

All resolutions were passed and decided by way of poll.

About Immutep

Immutep is a globally active biotechnology company that is a leader in the development of LAG-3 related immunotherapeutic products for the treatment of cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 fusion protein (LAG-3Ig), which is a first-in-class antigen presenting cell (APC) activator being explored in cancer and infectious disease. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.

Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.

Further information can be found on the Company’s website www.immutep.com or by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS
+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; tim@lifesciadvisors.com

This announcement was authorised for release by Deanne Miller, COO & Company Secretary of Immutep Limited.

Immutep Limited
Annual General Meeting
Friday, 26 November 2021
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

| Resolution details | | Instructions given to validly appointed proxies (as at proxy close) | | | | Direct votes (as at close of direct voting) | | | Number of votes cast on the poll (where applicable) | | | Resolution Result | If s250U applies |
|--|--------------------|--|------------|-----------------------|------------|--|---------|-----------|--|----------------------|------------|--------------------------|---------------------|
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain | For | Against | Abstain* | Carried / Not Carried | |
| 1. Adoption of Remuneration Report | Ordinary | 274,582,622 | 1,160,762 | 1,803,064 | 843,134 | 9,845,075 | 127,337 | 30,024 | 286,579,383 99.55% | 1,290,099 0.45% | 873,158 | Carried | No |
| 2. Re-election of Director - Dr Russell Howard | Ordinary | 279,327,851 | 1,459,484 | 1,905,023 | 899,642 | 20,861,709 | 3,235 | 7,443 | 302,445,205 99.52% | 1,462,719 0.48% | 907,085 | Carried | NA |
| 3. Ratification of previous Share issue | Ordinary | 218,401,812 | 2,041,473 | 1,659,093 | 57,037,067 | 20,373,847 | 310,667 | 187,873 | 240,785,374 99.03% | 2,352,140 0.97% | 57,224,940 | Carried | NA |
| 4. Approval of grant of performance rights to Dr Russell Howard | Ordinary | 272,208,059 | 7,149,516 | 1,855,950 | 1,628,475 | 20,026,155 | 818,873 | 27,359 | 294,563,786 97.43% | 7,770,389 2.57% | 1,730,834 | Carried | NA |
| 5. Approval of the use of performance rights and/or options under the Company's Executive Incentive Plan | Ordinary | 273,775,534 | 7,596,947 | 1,865,950 | 353,569 | 9,545,972 | 582,987 | 2,989,664 | 285,461,078 97.21% | 8,181,934 2.79% | 3,418,233 | Carried | NA |
| 6. Approval of grant of performance rights to Mr Marc Voigt | Ordinary | 220,099,588 | 60,109,222 | 1,583,939 | 1,799,251 | 20,036,491 | 808,537 | 27,359 | 242,193,640 79.95% | 60,719,759 20.05% | 1,901,610 | Carried | NA |
| 7. Approval of Amendment to Constitution | Special | 273,727,014 | 7,591,483 | 1,521,081 | 752,422 | 20,459,980 | 333,623 | 78,784 | 296,058,697 97.39% | 7,925,106 2.61% | 831,206 | Carried | NA |
| 8. Approval of Proportional Takeover Provisions | Special | 279,890,215 | 1,522,645 | 1,521,081 | 658,059 | 20,505,118 | 278,855 | 88,414 | 302,267,036 99.41% | 1,801,500 0.59% | 746,473 | Carried | NA |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.